Radiation therapy after radical prostatectomy: unresolved issues illustrated by clinical cases

Background. Despite advances and improvements in diagnostic and treatment methods, prostate cancer (PC) continues to be one of the most prevalent malignancies in men. The main treatment modalities for patients with localized and locally advanced PC are radical prostatectomy (RP), radiation therapy, and hormone therapy. After surgery, postoperative conformal external beam radiation therapy (EBRT) may be required in more than half of cases, taking into account individual risk factors.

Discussion. Currently, there is an ongoing discussion regarding the indications and optimal timing of radiation therapy after RP: whether it should be administered in the adjuvant setting (i.e., when there is no disease recurrence, but unfavorable prognostic factors are present), or as so-called salvage radiation therapy, in cases of biochemical recurrence or macroscopically detectable tumors. We analyzed the most well-known international studies devoted to this issue. The lack of convincing data supporting the benefit of adjuvant EBRT in improving survival after RP, even in the presence of unfavorable factors, contributes to the ongoing debate about its appropriateness, given the known increased risk of treatment-related complications and the deterioration in patients’ quality of life. Clinical case descriptions. We present clinical cases illustrating the use of both adjuvant and salvage radiation therapy.

Conclusion. After radical prostatectomy, adjuvant radiation therapy may be recommended for patients with unfavorable risk factors for recurrence. However, salvage radiation therapy reduces the risk of treatment-related complications, allows for dose escalation, and in nearly half of cases, helps avoid unnecessary and costly treatment.

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–24. doi: 10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020; 70(4): 313. doi: 10.3322/caac.21609.

2. Cancer care for the population of Russia in 2023. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2024. 262 p. (in Russian). ISBN: 978-5-85502-297-1.

3. Malignant tumors in Russia in 2023 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2024. 276 p. (in Russian). ISBN: 978-585502-298-8.

4. Tamayo-Jover M.A., González Álvarez R.J., Nazco Deroy Á., Plata Bello A.C., Álvarez-Arguelles H., García Álvarez C., Jimenez Sosa A., Castro-Díaz D.M., Concepción Masip T. Pathological findings in very low risk prostate cancer in surgical specimens. Arch Esp Urol. 2020; 73(7): 593–99.

5. Mauermann J., Fradet V., Lacombe L., Dujardin T., Tiguert R., Tetu B., Fradet Y. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. Eur Urol. 2013; 64(1): 19–25. doi: 10.1016/j.eururo.2012.08.002.

6. Hoepffner J.L., Gaston R., Mugnier C., Rey D., Lopez L., Roche J.B., Riviere J., Piechaud P.T. Prostatectomie radicale mini-invasive: apport de l’assistance robotisée, résultats fonctionnels et oncologiques. Bull Cancer. 2016; 103(5): 461–68. doi: 10.1016/j.bulcan.2016.02.006.

7. Zdobinská T., Jarolím L., Novák V., Do Carmo J., Příman O., Veselý Š., Babjuk M. Risk of biochemical recurrence in patients with a positive surgical margin after radical prostatectomy. Rozhl Chir. 2022 Spring; 101(3): 129–33. doi: 10.33699/PIS.2022.101.3.129-133.

8. Celik S., Eker A., Bozkurt İ.H., Bolat D., Basmacı İ., Şefik E., Değirmenci T., Günlüsoy B. Factors affecting biochemical recurrence of prostate cancer after radical prostatectomy in patients with positive and negative surgical margin. Prostate Int. 2020; 8(4): 178–84. doi: 10.1016/j.prnil.2020.08.003.

9. Riedinger J.M., Eche N., Fulla Y., Thuillier F. Cinétique du PSA après prostatectomie totale. Ann Biol Clin (Paris). 2009; 67(1): 39–46. doi: 10.1684/abc.2009.0298.

10. Yamaguchi N., Yumioka T., Iwamoto H., Masago T., Morizane S., Honda M., Sejima T., Takenaka A. Biochemical Recurrence Prediction in High-Risk Prostate Cancer Patients, Following Robot-Assisted Radical Prostatectomy. Yonago Acta Med. 2016; 59(4): 288–95.

11. Guo H., Zhang L., Shao Y., An K., Hu C., Liang X., Wang D. The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis. PLoS One. 2024; 19(7): e0301653. doi: 10.1371/journal.pone.0301653.

12. John A., Milton T., Gupta A., Nguyen M.T., Stretton B., Hewitt J., Virgin J., Kovoor J., Catterwell R., Selth L., Callaghan M.O. Impact of positive surgical margin location after radical prostatectomy: a network meta-analysis. World J Urol. 2025; 43(1): 134. doi: 10.1007/s00345-025-05479-7.

13. Lian Z., Zhang H., He Z., Ma S., Wang X., Liu R. Impact of positive surgical margin location and perineural invasion on biochemical recurrence in patients undergoing radical prostatectomy. World J Surg Oncol. 2020; 18(1): 201. doi: 10.1186/s12957-020-01977-7.

14. Martini A., Gandaglia G., Fossati N., Scuderi S., Bravi C.A., Mazzone E., Stabile A., Scarcella S., Robesti D., Barletta F., Cucchiara V., Mirone V., Montorsi F., Briganti A. Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. Eur Urol Oncol. 2021; 4(1): 42–48. doi: 10.1016/j.euo.2019.03.006.

15. Hervás-Morón A., Domínguez-Rullán J., Santana V.D., Valero M., Vallejo C., Sancho S., Fuentes J.D.G., López-Campos F., Gallego M.C. Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data. World J Clin Oncol. 2022; 13(7): 652–62. doi: 10.5306/wjco.v13.i7.652.

16. Li H.Z., Qi X., Gao X.S., Li X.M., Qin S.B., Li X.Y., Ma M.W., Bai Y., Chen J.Y., Ren X.Y., Li X.Y., Wang D. Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2024; 118(3): 697–705. doi: 10.1016/j.ijrobp.2023.09.011.

17. Bolla M., van Poppel H., Collette L., van Cangh P., Vekemans K., Da Pozzo L., de Reijke T.M., Verbaeys A., Bosset J.F., van Velthoven R., Maréchal J.M., Scalliet P., Haustermans K., Piérart M.; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005; 366(9485): 572–78. doi: 10.1016/S0140-6736(05)67101-2.

18. Van der Kwast T.H., Bolla M., van Poppel H., van Cangh P., Vekemans K., Da Pozzo L., Bosset J.F., Kurth K.H., Schröder F.H., Collette L.; EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007; 25(27): 4178–86. doi: 10.1200/JCO.2006.10.4067.

19. Thompson I.M. Jr., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., Messing E., Forman J., Chin J., Swanson G., Canby-Hagino E., Crawford E.D. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006; 296(19): 2329–35. doi: 10.1001/jama.296.19.2329.

20. Wiegel T., Bartkowiak D., Bottke D., Bronner C., Steiner U., Siegmann A., Golz R., Störkel S., Willich N., Semjonow A., Stöckle M., Rübe C., Rebmann U., Kälble T., Feldmann H.J., Wirth M., Hofmann R., Engenhart-Cabillic R., Hinke A., Hinkelbein W., Miller K. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014; 66(2): 243–50. doi: 10.1016/j.eururo.2014.03.011.

21. Parker C.C., Clarke N.W., Cook A.D., Kynaston H.G., Petersen P.M., Catton C., Cross W., Logue J., Parulekar W., Payne H., Persad R., Pickering H., Saad F., Anderson J., Bahl A., Bottomley D., Brasso K., Chahal R., Cooke P.W., Eddy B., Gibbs S., Goh C., Gujral S., Heath C., Henderson A., Jaganathan R., Jakobsen H., James N.D., Kanaga Sundaram S., Lees K., Lester J., Lindberg H., Money-Kyrle J., Morris S., O’Sullivan J., Ostler P., Owen L., Patel P., Pope A., Popert R., Raman R., Røder M.A., Sayers I., Simms M., Wilson J., Zarkar A., Parmar M.K.B., Sydes M.R. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020; 396(10260): 1413–21. doi: 10.1016/S0140-6736(20)31553-1.

22. Sargos P., Chabaud S., Latorzeff I., Magné N., Benyoucef A., Supiot S., Pasquier D., Abdiche M.S., Gilliot O., Graff-Cailleaud P., Silva M., Bergerot P., Baumann P., Belkacemi Y., Azria D., Brihoum M., Soulié M., Richaud P. Adjuvant radiotherapy versus early salvage radiotherapy plus shortterm androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020; 21(10): 1341–52. doi: 10.1016/S1470-2045(20)30454-X.

23. Kneebone A., Fraser-Browne C., Duchesne G.M., Fisher R., Frydenberg M., Herschtal A., Williams S.G., Brown C., Delprado W., Haworth A., Joseph D.J., Martin J.M., Matthews J.H.L., Millar J.L., Sidhom M., Spry N., Tang C.I., Turner S., Wiltshire K.L., Woo H.H., Davis I.D., Lim T.S., Pearse M. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020; 21(10): 1331–40. doi: 10.1016/S1470-2045(20)30456-3.